{
}
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted a strong recovery in the prescription trend for GLP-1 weight loss drugs, marking the best figures of the year, though she refrained from declaring a definitive trend reversal.
UBS has maintained a "Neutral" rating for Bayer, setting a price target of 22 euros. Analyst Jo Walton noted that Bayer's 2024 business figures met adjusted market expectations, with slight improvements in the pharmaceuticals sector and operating free cash flow, though the forecast for lower free cash flow this year was disappointing.
UBS has maintained a 'Buy' rating for Novo Nordisk, setting a target price of 750 Danish crowns. Despite this, the company has recently underperformed compared to Eli Lilly in the initial prescriptions of GLP-1 class weight loss drugs, leading to a slightly disappointing overall development.
UBS has maintained its "Buy" rating for Novo Nordisk, setting a target price of 750 Danish crowns. Analyst Jo Walton noted that Novo Nordisk has recently underperformed compared to Eli Lilly in the initial prescriptions of GLP-1 class weight loss drugs, indicating a slightly disappointing overall development.
UBS has maintained a "Neutral" rating on Bayer shares with a target price of 22 euros, citing a positive outlook for the company's CropScience division. Analyst Jo Walton noted the confidence stemming from competitor Corteva, as Bayer shares rose 2.2% to EUR 22.77 ahead of the upcoming Q4 2024 figures, set to be released on March 5, 2025.
UBS AG has maintained a "Neutral" rating for Bayer shares with a target price of 22 euros, anticipating a positive outlook for the company's CropScience division. Bayer shares rose 1.5% in XETRA trading, though they still face a potential downside of 2.74% relative to the target price. The company is set to release its Q4 2024 key figures on March 5, 2025.
UBS has maintained a "Neutral" rating for Bayer, setting a target price of 22 euros. Analyst Jo Walton anticipates a positive outlook for Bayer's CropScience division, influenced by confidence from competitor Corteva, ahead of the company's annual results.
UBS AG has maintained a "Neutral" rating for Bayer shares with a target price of €22, anticipating a positive outlook for its CropScience division. Bayer shares rose 1.6% to €22.63, indicating a downside risk of 2.78% relative to the target price. The company is set to release its Q4 2024 financial results on March 5, 2025.
UBS has maintained a 'Neutral' rating for Bayer, setting a target price of 22 euros, anticipating a positive outlook for its CropScience division ahead of the annual results. Analyst Jo Walton noted the confidence from competitor Corteva as a contributing factor. Bayer's sales are primarily from agricultural products (48.8%) and pharmaceuticals (38%), with significant market presence in the U.S. (30.6%).
UBS AG has maintained a "Neutral" rating on Bayer shares with a target price of 22 euros, anticipating a positive outlook for the company's crop protection business. As of midday trading, Bayer shares rose by 1.5% to EUR 22.62, reflecting a 17.1% increase since the start of 2025. The upcoming Q4 2024 key figures are set to be released on March 5, 2025.
Jo Walton
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS maintains buy rating for Novo Nordisk with target price of 750 crowns
14:48 07.03.2025
UBS maintains neutral rating for Bayer with price target of 22 euros
09:04 06.03.2025
ubs maintains buy rating for novo nordisk with target price of 750 kroner
17:05 03.03.2025
ubs maintains buy rating for novo nordisk with target price of 750 crowns
16:56 03.03.2025
ubs downgrades bayer shares to neutral with target price of 22 euros
18:58 25.02.2025
ubs maintains neutral rating for bayer with target price of 22 euros
13:26 25.02.2025
ubs maintains neutral rating for bayer with target price of 22 euros
12:00 25.02.2025
ubs maintains neutral rating for bayer shares with target price of 22 euros
11:52 25.02.2025
ubs maintains neutral rating for bayer with target price of 22 euros
11:48 25.02.2025
ubs maintains neutral rating on bayer shares with target price of 22 euros
10:28 25.02.2025
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Banking Regulations
Market Analysis and Predictions
Industry Mergers & Acquisitions
Global Trade Developments
Energy Sector Developments
Startups & Entrepreneurship
Government Policies
Supply Chain Management
Financial Scams and Security
Domestic Politics
Government Economic Policies
Central Bank Actions
Hedge Funds & Private Equity
Countries:
Companies:
Tesla, Inc.
Barclays PLC
JPMorgan Chase & Co.
Apple Inc.
BNP Paribas SA
UBS Group AG
NVIDIA Corporation
Morgan Stanley
Bank of America Corporation
Capital One Financial Corporation
The Goldman Sachs Group, Inc.
Deutsche Bank RV Global PP
Amazon.com, Inc.
Citigroup Inc.
Commerzbank AG
SpaceXCoin USD
Credit Suisse Real Estate Fund Siat
Wells Fargo & Company
UniCredit S.p.A.
Microsoft Corporation
Currencies:
United States Dollar
Euro
Chinese Yuan
Indian Rupee
Swiss Franc
British Pound Sterling
Vietnamese Đồng
Hong Kong Dollar
Australian Dollar
United Arab Emirates Dirham
Japanese Yen
Singapore Dollar
South Korean Won
Thai Baht
Norwegian Krone
Danish Krone
Swedish Krona
Russian Ruble
Ghanaian Cedi
Canadian Dollar
People: